LEN vs TNGX · rev $14.56B vs $5.36B cap
LEN (LEN) versus Tango Therapeutics Inc (TNGX) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Tango Therapeutics Inc (TNGX) is a biotechnology company listed on NASDAQ.
Latest reported LEN revenue for 2026-05-31 was $14.56B. Net income was $534.2M. LEN currently screens at market cap $0.
Latest reported TNGX revenue for 2026-06-30 was $0. Net income was -$100.9M. TNGX currently screens at market cap $5.36B.
LEN currently screens at market cap $0. TNGX currently screens at market cap $5.36B.
Not investment advice. Open the LEN and TNGX stock pages for the full models.
Not investment advice.